Pharmafile Logo

Research Partnership is on the rise

December 21, 2021 | Mark Jeffrey, Pharma, global healthcare 

Research Partnership ranks 12th in fastest growing UK market research agency league  tables

The UK’s best performing market research agencies were revealed this week with the publication of Research Live’s Industry Report for 2021, which includes the latest Market Research Society (MRS) League Tables. Based on available 2020 financial data that was compiled and analysed in November 2021, the MRS league tables identify and rank the best-performing research agencies and businesses according to their UK-based turnover and by their year-on-year growth.

In a very challenging year globally, Research Partnership bucked the trend by achieving an impressive 21% growth against an industry average of 0.8%. Less than half of the top 100 companies reported any growth.

Research Partnership ranked 23rd in the top individual agencies with a confirmed turnover of £40.297m and remains the UK’s largest individual healthcare consulting specialist.

The company ranked 7th in the top 20 fastest-growing businesses and 12th in the top 20 fastest-growing individual agencies.

Joint Founding Director Mark Jeffery commented, “Research Partnership has achieved considerable growth in a very turbulent climate. Fortunately, we were able to pivot quickly to remote working using online methodologies and we responded effectively to increased demand from our clients. Last year, we continued our recruitment drive and increased our headcount from 216 to 250 with appointments made across the US, EU and APAC offices. We also continued to grow both our market research and market access services, and we are winning business from both new and existing clients across the pharmaceutical, medtech and biotech sectors. According to our customer survey, satisfaction with insights and recommendations remained high and we are still delivering the quality service expected of us.”

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Video: Immuno-oncology therapies

Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high...

Event: EULAR Annual European Congress of Rheumatology 2016

We are delighted to be attending the EULAR Annual European Congress of Rheumatology in June. Representing Research Partnership is Business Development Manager, Fara Mboge. He will be on hand to...

Forever Angels achievements and development plan for 2016

Research Partnership is proud to support Forever Angels in their mission of caring for and improving the lives of orphans and abandoned infants in Tanzania

The Opportunity for Women’s Health in Emerging Markets

Published in eyeforpharma April 2016 by Rachel Howard

Video: Storytelling in healthcare market research

Within the pharmaceutical industry, there is an increasing need for market research teams to share the insights with their key internal stakeholders, from marketing and brand managers to sales reps...

Promotions and new appointments across our global offices

Research Partnership is delighted to announce promotions and new starters in the UK and further appointments in the US and Singapore offices

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...

Webcast: Understanding the Chronic Disease Patient Journey in Emerging Markets

In emerging markets where primary care systems do not exist, the patient is the only constant in the journey

Living with Crohn’s Report

Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?

Infographic: Research Partnership

Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.